Sales and debt. Are the sales growing year after year, and can the company carry what it owes? Then I look at the cash coming in before I look at profit. If a business can’t bring in real cash and carry its debt, I’m not that interested. I check if the company is cheap or expensive at the end.
ResMed and Biogen
Someone new to investing listed the stocks they owned and asked what to look out for. Two of them went in opposite directions.
ResMed makes machines for sleep apnea. Its sales have grown every year for more than a decade, from $1.68 billion in fiscal 2015 to $5.65 billion in fiscal 2026, which ended in June, according to its annual report for fiscal 2026. At the end of June 2026 it owed $659 million and had $1.47 billion in cash.
Biogen, which sells drugs for multiple sclerosis and other diseases of the brain and nerves, had $14.38 billion of sales in 2019. In 2025 it had $9.89 billion, 31% less, its 2025 annual report shows.
When sales grow and cash falls
Amazon’s sales kept growing in 2025. They rose 12%, to $716.9 billion. Its free cash flow fell by about 70%, from $38.2 billion in 2024 to $11.2 billion in 2025. Its fourth-quarter release says that’s because it spent so much more on property and equipment, mostly for AI. With Amazon, follow what all that spending turns into, year by year.
If I were starting out, I’d keep my new money going into index funds while I learned to pick single stocks, and I’d practice by reading the sales, debt and cash lines of a few companies I know.
Where this breaks
Sales and debt won’t tell you if the company is cheap or expensive. A company can grow every year with little debt and still be expensive.